MLTX

MoonLake Immunotherapeutics

NASDAQ: MLTX · HEALTHCARE · BIOTECHNOLOGY

$11.56

-3.99% today

Updated 2026-09-28

Market cap

$1.06B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.84

Dividend yield

—

52W range

$6 – $63

Volume

1.4M

Market cap

$1.06B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.84

Dividend yield

—

52W range

$6 – $63

Volume

1.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-0.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →261 stocks currently score above 75

Price targets

Analyst target

$28.54

+146.89%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy10 Buy2 Hold2 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.24x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -0.67 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-55.56M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-64.51M	$-36.01M	$-118.94M	$-227.32M	$-61.80M
EPS	—	—	—	—	$-3.84
Free cash flow	$-55.91M	$-43.06M	$-117.11M	$-196.04M	$-55.56M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MLTX	$1.06B	28	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.03T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$648.67B	59	4.7	8.5	3.7	5.5	—	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-73.51%	Strong Buy
MRK	$365.34B	36	4.0	4.5	2.0	5.0	-78.20%	Hold
UNH	$333.27B	62	7.3	5.5	5.3	5.5	-14.85%	Buy

Smart narrative

MoonLake Immunotherapeutics trades at $11.56. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.67, it sits in the distress.

Frequently asked questions

What is MoonLake Immunotherapeutics's stock price?

MoonLake Immunotherapeutics (MLTX) trades at $11.56.

Is MoonLake Immunotherapeutics overvalued?

MoonLake Immunotherapeutics carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of MoonLake Immunotherapeutics (MLTX)?

The 12-month analyst consensus target is $28.54, about 146.9% above the current $11.56. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

MoonLake Immunotherapeutics's Altman Z-Score is -0.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-77.80%

Beta1.04

50D MA$16.95

200D MA$16.89

Shares out0.09B

Float0.06B

Short ratio—

Avg volume1.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MLTX vs LLY →MLTX vs JNJ →MLTX vs ABBV →Stock screener →